No adequate evidence indicating hypertension as an independent risk factor for COVID-19 severity.
作者信息
Li Gerui, Li Hang, Lu Jinping
机构信息
Department of Cardiology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.
Department of Geratology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.
出版信息
Clin Res Cardiol. 2021 Jan;110(1):146-147. doi: 10.1007/s00392-020-01653-6. Epub 2020 Apr 23.
Abstract
摘要
相似文献
1
No adequate evidence indicating hypertension as an independent risk factor for COVID-19 severity.
Clin Res Cardiol. 2021 Jan;110(1):146-147. doi: 10.1007/s00392-020-01653-6. Epub 2020 Apr 23.
2
Is hypertension without any other comorbidities an independent predictor for COVID-19 severity and mortality?
J Clin Hypertens (Greenwich). 2021 Feb;23(2):232-234. doi: 10.1111/jch.14144. Epub 2020 Dec 23.
3
The influence of diabetes and hypertension on outcome in COVID-19 patients: Do we mix apples and oranges?
J Clin Hypertens (Greenwich). 2021 Feb;23(2):235-237. doi: 10.1111/jch.14145. Epub 2020 Dec 25.
4
Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China.
Allergy. 2020 Jul;75(7):1730-1741. doi: 10.1111/all.14238. Epub 2020 Feb 27.
5
[Diabetes and hypertension as factors associated with Covid-19 lethality in Sonora, Mexico, 2020].
Salud Publica Mex. 2020 Sep-Oct;62(5):456-457. doi: 10.21149/11546.
6
ACE Gene Variants Rise the Risk of Severe COVID-19 in Patients With Hypertension, Dyslipidemia or Diabetes: A Spanish Pilot Study.
Front Endocrinol (Lausanne). 2021 Aug 19;12:688071. doi: 10.3389/fendo.2021.688071. eCollection 2021.
7
Impact of cardiovascular and metabolic diseases on the severity of COVID-19: a systematic review and meta-analysis.
Aging (Albany NY). 2020 Nov 16;12(22):23409-23421. doi: 10.18632/aging.103991.
8
Environmental pollution and COVID-19: the molecular terms and predominant disease outcomes of their sweetheart agreement.
Epidemiol Prev. 2020 Sep-Dec;44(5-6 Suppl 2):169-182. doi: 10.19191/EP20.5-6.S2.116.
9
COVID-19 (SARS-CoV-2) infection and thrombotic conditions: A systematic review and meta-analysis.
Eur J Clin Invest. 2021 Jun;51(6):e13559. doi: 10.1111/eci.13559. Epub 2021 Apr 14.
10
Response to: Is newly diagnosed diabetes a stronger risk factor than pre-existing diabetes for COVID-19 severity?
J Diabetes. 2021 Feb;13(2):179-180. doi: 10.1111/1753-0407.13127. Epub 2020 Nov 18.
引用本文的文献
1
Effect of Underlying Cardiovascular Disease on the Prognosis of COVID-19 Patients; a Sex and Age-Dependent Analysis.
Arch Acad Emerg Med. 2021 Sep 30;9(1):e65. doi: 10.22037/aaem.v9i1.1363. eCollection 2021.
2
Arterial hypertension - Clinical trials update 2021.
Nutr Metab Cardiovasc Dis. 2022 Jan;32(1):21-31. doi: 10.1016/j.numecd.2021.09.007. Epub 2021 Sep 16.
3
The Impact of Obesity and Lifestyle on the Immune System and Susceptibility to Infections Such as COVID-19.
Front Nutr. 2020 Nov 19;7:597600. doi: 10.3389/fnut.2020.597600. eCollection 2020.
4
Disturbing effect of lockdown for COVID-19 on the incidence of infective endocarditis: a word of caution.
Clin Res Cardiol. 2020 Dec;109(12):1573-1576. doi: 10.1007/s00392-020-01686-x. Epub 2020 Jun 10.
5
The mystery of "missing" visits in an emergency cardiology department, in the era of COVID-19.; a time-series analysis in a tertiary Greek General Hospital.
Clin Res Cardiol. 2020 Dec;109(12):1483-1489. doi: 10.1007/s00392-020-01682-1. Epub 2020 Jun 6.
6
Management recommendations for patients with chronic kidney disease during the novel coronavirus disease 2019 (COVID-19) epidemic.
Chronic Dis Transl Med. 2020 May 13;6(2):119-123. doi: 10.1016/j.cdtm.2020.05.001. eCollection 2020 Jun.
本文引用的文献
1
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
Lancet Respir Med. 2020 Apr;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11.
2
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.
JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994.
3
Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.
Clin Res Cardiol. 2020 May;109(5):531-538. doi: 10.1007/s00392-020-01626-9. Epub 2020 Mar 11.
4
[Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19].
Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Jul 24;48(7):567-571. doi: 10.3760/cma.j.cn112148-20200225-00123.
5
Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target.
Intensive Care Med. 2020 Apr;46(4):586-590. doi: 10.1007/s00134-020-05985-9. Epub 2020 Mar 3.
6
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury.
Nat Med. 2005 Aug;11(8):875-9. doi: 10.1038/nm1267. Epub 2005 Jul 10.
Zotero 插件